Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial

Enrolling by invitation · Phase 2

Conditions studied: Sebaceous Hyperplasia

In brief

The purpose of this study is to compare treatment of sebaceous hyperplasia with pulsed dye laser (PDL) plus neodymium doped yttrium aluminum garnet laser (Nd:YAG) versus erbium doped yttrium aluminum garnet (erbium:YAG) laser versus electrodesiccation and curettage (ED\&C). This is a randomized clinical trial. Approximately 18 participants will enrolled. Each participant will have their sebaceous hyperplasia lesions randomized to receive either Erbium:YAG, PDL plus Nd:YAG, or ED\&C treatment. Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Lesions will be treated twice, 2-6 weeks after the first treatment. Lesion size and count will be measured before treatment and at follow-up 4-12 weeks after the first treatment. This study is a pilot study designed to determine the feasibility of these procedures. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

Key facts

Study ID

NCT04429607

Run by

Northwestern University

People needed

18

Starts

2025-10-23

Expected to finish

2026-12-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• ≥18 years of age
• Receiving cosmetic treatment for sebaceous hyperplasia
• In good general health as assessed by the investigator
• Participants must have the ability to understand and the willingness to sign a written informed consent prior to registration on study

You may not qualify if…

• Patient pregnant or nursing
• Patient with history of poor wound healing that would result in hypertrophic scar or keloid at the discretion of the physician
• Patient with recent sun exposure that would result in pigment changes at the discretion of the physician
• Subject unwilling to sign an IRB approved consent form
• Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible

Where it is running

• Northwestern University Department of Dermatology — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.